FDA to Expand High Performance Computing to Boost Clinical Trial Efficiency

The FDA plans to expand its capabilities in high performance computing to help build disease models and simulate device clinical trials as part of an agency initiative announced Friday by Commissioner Scott Gottlieb.

The project will focus on modernizing the agency’s regulatory processes and reducing the time, cost and uncertainty of bringing a product to market.

CDRH is building in silico regulatory models for product design and evaluation, including the development of a digital library of models and a family of virtual patients for device testing, Gottlieb said.